Olumiant Side Effects

Generic name: baricitinib

Medically reviewed by Drugs.com. Last updated on Jun 15, 2023.

Note: This document provides detailed information about Olumiant Side Effects associated with baricitinib. Some dosage forms listed on this page may not apply specifically to the brand name Olumiant.

Applies to baricitinib: oral tablet.

Important warnings This medicine can cause some serious health issues

Oral route (tablet)

Serious Infections. Patients treated with baricitinib are at risk for developing serious infections that may lead to hospitalization or death.

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.If a serious infection develops, interrupt baricitinib until the infection is controlled.Reported infections include:Active tuberculosis, which may present with pulmonary or extrapulmonary disease.

Baricitinib should not be given to patients with active tuberculosis.

Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating baricitinib and during therapy.

If positive, start treatment for latent infection prior to baricitinib use.Invasive fungal infections, including candidiasis and pneumocystosis.

Patients with invasive fungal infections may present with disseminated, rather than localized, disease.Bacterial, viral, and other infections due to opportunistic pathogens.The risks and benefits of treatment with baricitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with baricitinib including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapyMortality. In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death ,was observed with the JAK inhibitorMalignancies Lymphoma and other malignancies have been observed in patients treated with baricitinib.

In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers.

Patients who are current or past smokers are at additional increased risk.Major Adverse Cardiovascular Events. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed when compared with TNF blockers.

Patients who are current or past smokers are at additional increased risk.

Discontinue baricitinib in patients that have experienced a myocardial infarction or stroke.Thrombosis. Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with baricitinib compared to placebo.

In addition, there were cases of arterial thrombosis.

Many of these adverse events were serious and some resulted in death.

In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers.

Avoid baricitinib in patients at risk.

Patients with symptoms of thrombosis should discontinue baricitinib and be promptly evaluated.

Serious side effects of Olumiant

Along with its needed effects, baricitinib (the active ingredient contained in Olumiant) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking baricitinib:

More common side effects

• body aches or pain
• chest tightness
• chills
• cough
• difficulty in breathing
• ear congestion
• fever
• headache
• hoarseness
• loss of voice
• muscle aches
• pain or tenderness around the eyes and cheekbones
• runny or stuffy nose
• sneezing
• sore throat
• trouble in swallowing
• unusual tiredness or weakness

Less common side effects

• black, tarry stools
• bladder pain
• blemishes on the skin
• bloody or cloudy urine
• burning, itching, and pain in hairy areas, pus at the root of the hair
• chest pain or tightness
• cough producing mucus
• difficult, burning, or painful urination
• frequent urge to urinate
• itching of the vagina or outside genitals
• lower back or side pain
• pain, redness, or swelling in the arm or leg
• pain during sexual intercourse
• pains in the chest, groin, or legs, especially calves of the legs
• pale skin
• pimples
• severe headaches of sudden onset
• stomach pain
• sudden loss of coordination
• sudden onset of slurred speech
• sudden vision changes
• thick, white curd-like vaginal discharge without odor or with mild odor
• trouble breathing
• unusual bleeding or bruising

Rare side effects

• anxiety
• burning or stinging of the skin
• coughing or spitting up blood
• dizziness or lightheadedness
• increased weight
• night sweats
• painful blisters on the trunk of body
• painful cold sores or blisters on the lips, nose, eyes, or genitals
• sudden high fever or low-grade fever for months

Incidence not known

• chest discomfort
• confusion
• difficulty in speaking
• double vision
• inability to move the arms, legs, or facial muscles
• inability to speak
• large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
• nausea
• no blood pressure or pulse
• pain or discomfort in the arms, jaw, back or neck
• persistent non-healing sore
• pink growth
• reddish patch or irritated area
• shiny bump
• stopping of heart
• sweating
• unconsciousness
• white, yellow, or waxy scar-like area

For healthcare professionals

Applies to baricitinib: oral tablet.

Cardiovascular adverse events

• Common (1% to 10%): Hypertension, coronary artery disease, deep vein thrombosis (DVT)
• Frequency not reported: Venous thromboses/venous thromboembolism, arterial thrombosis, venous thromboembolic events, myocardial infarction

Venous thromboses, venous thromboembolism, and venous thromboembolic events included DVT and pulmonary embolism.

Dermatologic

• Common (1% to 10%): Herpes simplex, acne, rash, alopecia, onychomycosis, contact dermatitis, folliculitis, pruritus
• Uncommon (0.1% to 1%): Urticaria
• Frequency not reported: Fungal skin infections

Herpes simplex included eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, oral herpes, Kaposi's varicelliform eruption, and genital herpes simplex.

Acne included acne, acne varioliformis, and dermatitis acneiform.

Rash included rash, dermatitis, contact dermatitis, eczema, allergic dermatitis, maculopapular rash, pruritic rash, pustular rash, drug eruption, erythematous rash, and macular rash.

Folliculitis was most commonly localized in the scalp region associated with hair regrowth.

Gastrointestinal

• Common (1% to 10%): Nausea, gastroenteritis, diarrhea, dyspepsia, abdominal pain, constipation, vomiting, stomatitis, abdominal discomfort, gastroesophageal reflux disease, upper abdominal pain, oral herpes
• Uncommon (0.1% to 1%): Diverticulitis
• Frequency not reported: Gastrointestinal perforations

Abdominal pain included abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal discomfort.

Genitourinary

• Common (1% to 10%): Urinary tract infection, cystitis, benign prostatic hyperplasia, erectile dysfunction, vulvovaginal candidiasis, genital Candida infections, irregular menstruation

Urinary tract infection included cystitis, urinary tract infection, urine positive for WBCs, bacterial urinary tract infection, and pyelonephritis.

Genital Candida infections included vulvovaginal candidiasis, vulvovaginal mycotic infection, and genital fungal infection.

Hematologic

• Common (1% to 10%): Thrombocytosis, neutropenia, anemia, iron deficiency anemia, increased platelet count, increased WBC count
• Frequency not reported: Lymphopenia, lymphocytosis

Thrombocytosis (greater than 600,000 cells/mm3) and neutropenia (less than 1000 cells/mm3) were reported in up to 7.9% and 2.2% of patients, respectively.

Neutropenia included neutropenia and decreased neutrophil count.

Hepatic

• Very common (10% or more): Increased ALT (up to 18.1%), increased AST (up to 11.8%)
• Common (1% to 10%): Abnormal hepatic function, increased liver enzymes, increased transaminases

Increased ALT (at least 3 times the upper limit of normal [3 x ULN]) and increased AST (at least 3 x ULN) were reported in up to 18.1% and 11.8% of patients, respectively.

Increased liver enzymes included increased transaminases, increased AST, increased ALT, increased hepatic enzyme, increased GGT, and abnormal hepatic function.

Hypersensitivity

• Postmarketing reports: Drug hypersensitivity (e.g., rash, urticaria, angioedema)

Metabolic

• Very common (10% or more): Hypercholesterolemia
• Common (1% to 10%): Hyperlipidemia, dyslipidemia
• Uncommon (0.1% to 1%): Hypertriglyceridemia

Hyperlipidemia included hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, increased lipids, increased low-density lipoprotein, increased blood cholesterol, and increased blood triglycerides.

Musculoskeletal

• Common (1% to 10%): Arthralgia, rheumatoid arthritis, back pain, muscle spasms, increased creatine phosphokinase, osteoarthritis
• Uncommon (0.1% to 1%): Myalgia

Increased creatine phosphokinase (greater than 5 x ULN) was reported in up to 5.1% of patients.

Nervous system

• Common (1% to 10%): Headache, dizziness, sciatica

Ocular

• Common (1% to 10%): Blurred vision, cataract

Oncologic

• Frequency not reported: Malignancies, nonmelanoma skin cancers, B-cell lymphoma

Other

• Very common (10% or more): Increased low-density lipoprotein (LDL) cholesterol (up to 33.7%), infections (up to 31.5%)
• Common (1% to 10%): Fatigue, pyrexia, peripheral edema, serious infections, septic shock, contusion, drug intolerance, increased blood alkaline phosphatase, increased blood cholesterol, herpes zoster, increased weight
• Uncommon (0.1% to 1%): Opportunistic infections, tuberculosis, swelling of the face, increased triglycerides
• Frequency not reported: Increased lipid parameters, viral reactivation

During 12 weeks of therapy, up to 33.7% of patients developed LDL cholesterol at least 130 mg/dL (3.36 mmol/L). Increased triglycerides (at least 500 mg/dL [5.65 mmol/L]) was reported in at least 0.7% of patients.

Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving this drug; the most common serious infections reported included pneumonia, herpes zoster, cellulitis, and urinary tract infection.

Infections included bacterial, mycobacterial, invasive fungal, viral, and opportunistic.

Opportunistic infections included tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystis pneumonia/pneumocystosis, acute histoplasmosis, cryptococcosis, CMV, and BK virus.

Swelling of the face included eye swelling, eyelid edema, face edema, lip swelling, swelling face, and swelling of eyelid.

In the integrated data from rheumatoid arthritis, atopic dermatitis, and alopecia areata clinical trials, this drug was associated with dose-related increases in lipid parameters (including total cholesterol, LDL cholesterol, and high-density lipoprotein cholesterol); in rheumatoid arthritis trials, this drug was also associated with dose-related increases in triglycerides. Elevations were observed at 12 weeks and remained stable thereafter at a higher value than baseline in rheumatoid arthritis trials; total and LDL cholesterol increased through week 52 in atopic dermatitis patients and alopecia areata patients.

Viral reactivation (including herpes virus reactivation [e.g., herpes zoster, herpes simplex]) has been reported.

Psychiatric

• Common (1% to 10%): Depression
• Uncommon (0.1% to 1%): Insomnia

Renal

• Frequency not reported: Increased serum creatinine, decreased cystatin C

Respiratory

• Very common (10% or more): Upper respiratory tract infections (up to 21.3%)
• Common (1% to 10%): Bronchitis, nasopharyngitis, pharyngitis, sinusitis, rhinitis, cough, pneumonia, oropharyngeal pain, influenza, COVID-19 pneumonia, pulmonary embolism, tonsillitis, dyspnea, rhinorrhea, lower respiratory tract infections, viral upper respiratory tract infection

Upper respiratory tract infections included acute sinusitis, chronic sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection, influenza, viral upper respiratory tract infection, viral sinusitis, viral pharyngitis, viral respiratory tract infection, rhinovirus infection, and adenoiditis.

Lower respiratory tract infections included bronchitis, bronchiolitis, lower respiratory tract infection, pneumonia, COVID-19 pneumonia, and respiratory tract infection.

Frequently asked questions

• What are the new drugs for rheumatoid arthritis (RA)?
• What are JAK inhibitors and how do they work?
• Which JAK inhibitors are approved in the U.S?
• How effective is Olumiant for Alopecia Areata (hair loss)?
• Is baricitinib (Olumiant) being used to treat COVID-19?
• What type of drug is Olumiant (baricitinib)?

Further information

Olumiant side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer